De novo macrocyclic peptide discovery produces potent class A GPCR ligands with diverse pharmacology
Fernando Salgado-Polo, Marin Matic, Philip Rainsford, Felix Faas, Max Meyrath, Rajesh Regmi, METTE MARIE ROSENKILDE, Martyna Szpakowska, Andy Chevigné, Alexander S. Hauser, Joseph M. Rogers, Martin B Gustavsson
This study discovers potent, selective macrocyclic peptide ligands for CXCR4, a class A GPCR, demonstrating the feasibility of de novo peptide design for this receptor family.
bioRxiv · Oct 22, 2026 · PreprintPharmacology & Toxicology